Neoadjuvant BRAF-directed therapy followed by surgery has also been explored in stage IVb ATC, showing improved survival (12-month OS of 93.6% and PFS of 84.4%), reduced tumor size, and lower surgical morbidity, though outcomes were poorer in patients with residual disease post-surgery; these promising findings require validation in prospective trials [100]. This evidence concerns the gene BRAF and neoplasm.